Business Description
Delcath Systems Inc
NAICS : 621511
SIC : 8071
ISIN : US24661P8077
Total Employee Number:
156Description
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 38.94 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -1.73 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 17.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 133.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 22.91 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.69 | |||||
9-Day RSI | 54.64 | |||||
14-Day RSI | 59.2 | |||||
3-1 Month Momentum % | 9.62 | |||||
6-1 Month Momentum % | 34.38 | |||||
12-1 Month Momentum % | 9.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.83 | |||||
Quick Ratio | 8.95 | |||||
Cash Ratio | 7.22 | |||||
Days Inventory | 313.39 | |||||
Days Sales Outstanding | 54.65 | |||||
Days Payable | 100.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -51.1 | |||||
Shareholder Yield % | 0.57 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.05 | |||||
Operating Margin % | -1.9 | |||||
Net Margin % | 0.56 | |||||
EBITDA Margin % | -1.5 | |||||
FCF Margin % | 18.35 | |||||
OCF Margin % | 20.53 | |||||
ROE % | 0.47 | |||||
ROA % | 0.42 | |||||
ROIC % | -2.63 | |||||
3-Year ROIIC % | 220.09 | |||||
ROC (Joel Greenblatt) % | -7.39 | |||||
ROCE % | -1.58 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 1638 | |||||
Forward PE Ratio | 442.65 | |||||
PE Ratio without NRI | 1638 | |||||
Price-to-Owner-Earnings | 1489.09 | |||||
PS Ratio | 6.66 | |||||
PB Ratio | 4.68 | |||||
Price-to-Tangible-Book | 4.68 | |||||
Price-to-Free-Cash-Flow | 37.23 | |||||
Price-to-Operating-Cash-Flow | 33.16 | |||||
EV-to-EBIT | -261.81 | |||||
EV-to-EBITDA | -332.58 | |||||
EV-to-Revenue | 4.98 | |||||
EV-to-Forward-Revenue | 4.45 | |||||
EV-to-FCF | 27.13 | |||||
Price-to-GF-Value | 0.56 | |||||
Price-to-Graham-Number | 18.4 | |||||
| Price-to-Net-Current-Asset-Value | 4.95 | |||||
| Price-to-Net-Cash | 7.09 | |||||
Earnings Yield (Greenblatt) % | -0.38 | |||||
FCF Yield % | 3.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DCTH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Delcath Systems Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 95.418 | ||
| EPS (TTM) ($) | 0.01 | ||
| Beta | 1.257 | ||
| 3-Year Sharpe Ratio | 0.77 | ||
| 3-Year Sortino Ratio | 1.59 | ||
| Volatility % | 26.72 | ||
| 14-Day RSI | 59.2 | ||
| 14-Day ATR ($) | 0.645846 | ||
| 20-Day SMA ($) | 15.90675 | ||
| 12-1 Month Momentum % | 9.32 | ||
| 52-Week Range ($) | 8.12 - 17.42 | ||
| Shares Outstanding (Mil) | 34.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Delcath Systems Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Delcath Systems Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:30 | In 183 days | ||
| Annual report for 2026 | 2027-02-26 | In 182 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 182 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 69 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 68 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | 12.63 (-4.39%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 12.63 (-4.39%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 | 11.09 (-0.36%) | ||
| General meeting for 2026 | 2026-05-13 10:00 | 11.34 (+3.09%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 11.25 (-2.93%) |
Show
Entries
Delcath Systems Inc Frequently Asked Questions
What is Delcath Systems Inc(DCTH)'s stock price today?
The current price of DCTH is $16.38. The 52 week high of DCTH is $17.42 and 52 week low is $8.12.
When is next earnings date of Delcath Systems Inc(DCTH)?
The next earnings date of Delcath Systems Inc(DCTH) is 2026-11-04 Est..
Does Delcath Systems Inc(DCTH) pay dividends? If so, how much?
Delcath Systems Inc(DCTH) does not pay dividend.
Guru Commentaries on NAS:DCTH
2025 Q3
What the manager wrote
Delcath Systems (DCTH) is a commercial-stage oncology company focused on liver-directed cancer therapies. Its proprietary Hepzato Kit delivers high-dose chemotherapy directly to the liver while minimizing systemic exposure, allowing for targeted treatment of metastatic cancers. The therapy is currently approved for ocular melanoma with liver metastases, and ongoing trials are exploring its potential in broader indications. Despite recent underperformance due to near-term headwinds, we continue to like the name given its growing procedural volumes, improving revenue visibility, and the potential for strong CHOPIN results to expand use into first-line metastatic liver-directed therapy.
Press Release
Articles on Delcath Systems Inc
Rosalind Advisors, Inc. Expands Myomo Inc (MYO) Stake -- Shares Trade 48% Below GF Value
Aug 19, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers